Can favorite teen tunes help dementia patients? A Brown University study finds they can.
The university's ongoing study, '
how music can be used
as a non-pharmacological intervention for people with
Get Rhode Island News Alerts
Sign up to get breaking news and interesting stories from Rhode Island in your inbox each weekday.
Enter Email
Sign Up
McCreedy, who has a bachelor's degree in music therapy and psychology, was a music therapist and is a music lover who plays the flute, piano, and guitar.
Her experience with dementia is both 'professional and personal.' She had a grandmother who had Alzheimer's disease and used to play the organ at an Irish Catholic church in Chicago.
In later stages of dementia, McCreedy's grandmother could always connect with old Irish songs.
''
Advertisement
McCreedy shared the results of the initial phase of the study, which began and ended in 2019.
Q. Tell us about the Music and Memory study.
McCreedy:
The principal investigator for the Music and Memory study is Vincent Moore. We randomly assigned nursing homes to either receive the early preferred music intervention or the usual care, which could include group music. Individual patients might listen to music, but the real question was, can this early preferred music (ages 16 to 26) — the songs you listened to in high school with your friends, songs you got married to — be used at early signs of agitation, with the goal of reducing the burden of agitated behaviors in people living with dementia? And, can it help reduce the use of antipsychotics and other medications sometimes used to manage agitation, which can have dangerous side effects? The idea was, if we could intervene early with a safe and efficacious treatment, could we both decrease the behaviors and need for subsequent medication management?
What were some of the key findings?
The study showed that... early preferred music reduced the frequency of verbally agitated behaviors in people living in nursing homes who have dementia. That's the main finding. ... Then the question is, do you decrease the medications that sometimes are used to manage the behavior? We did look at antipsychotics and we found that it does look like it reduces it, but ... we
can't say definitively. We did not find that the intervention reduced physically agitated behaviors.
Advertisement
Which sites participated in the study?
It was 976 residents from 54 nursing homes, 27 treatment centers, and 27 control. They were in the Midwest, in the central D.C. metro area, and in the South. We had a pretty racially diverse sample. About 25 percent of our sample was African American.
What do you do if you don't know a resident's musical preference?
We have a paper that shows it took 2 1/2 hours on average – or two or three sittings – to find residents' musical preference. Often, you're in a situation where someone is a good candidate for intervention, but we don't have any idea what their musical preference is. We started with Billboard lists in different genres and different decades, and we've modified them to be a little more regionally specific, site specific, so we can get a bit more tailored to the top 10. An activity staff sat and played the music for the resident and looked for positive responses — tapping, vocalizations of any sort, just an awakening or increase in attention.
Do you see your research being used in emotion recognition apps, artificial intelligence, or mental health tools?
Yes, although I think that there's big barriers to scale here and so we're trying to target the different pieces that affect getting this to everybody, especially older adults living with dementia, wherever they are living. But there could be broader uses of preferred music for reducing isolation and loneliness in healthy adults. ... We have a pilot to look at smartwatches and map the human-observed agitation, which is what we do a lot of in our lab. There's a lot we could do if we know when a person is starting to get agitated. We're thinking about technology in the form of consumer wearables to detect agitation and making playlists based on affect and response.
Advertisement
Tell us about the effort that was needed to gather the data for this study?
This research would not be possible — 100 percent — without our nursing home partners and the staff that are already working so very hard. This is one of those environments that the people are doing the best work in, not getting enough pay for what they do. I would recommend everybody go and volunteer at a nursing home and see how hard these folks are working and how much they care.
This interview has been lightly edited for length and clarity.
The Boston Globe's weekly Ocean State Innovators column features a Q&A with Rhode Island innovators who are starting new businesses and nonprofits, conducting groundbreaking research, and reshaping the state's economy. Send tips and suggestions to
.
Carlos Muñoz can be reached at
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Miami Herald
2 days ago
- Miami Herald
Trump's science cuts are great news — for other countries
Of all the questionable things President Trump has done recently — such as starting trade wars with traditional U.S. allies, threatening to invade friendly countries and pushing for bills that would balloon the U.S. deficit — one of the most important, yet least discussed, is his defunding of U.S. science programs. Since the start of his second term on Jan. 20, Trump has set in motion the most sweeping cuts to scientific research in modern U.S. history, including public grants for research into Alzheimer's, cancer and other major diseases. In addition to cutting research funds for leading U.S. universities, such as Harvard and Princeton, Trump's 2026 budget has led to the planned layoffs of thousands of scientists at some of the world's leading scientific institutions. Many U.S. scientists are now moving to Canada and Europe, where leaders in France and other countries have already opened their doors —and their budgets— to America's scientific refugees. A White House document proposing the 2026 budget calls for a 57% reduction for the U.S. National Science Foundation (NSF), which supports basic research in science and engineering, from $9 billion to $3.9 billion. It also calls for a 40% cut in the funding for the National Institutes of Health (NIH), the world's biggest public funder of biomedical research, from $47 billion to $27 billion. To put these figures in perspective, Trump's 'Big, beautiful bill,' which was close to being passed by Congress at the time of this writing, included $45 billion in new funds to build detention facilities — critics call them 'concentration camps' — for undocumented immigrants. As I have shown in previous columns, most current immigration detainees are not violent criminals, but hard-working people seeking a better life. Already, the NIH has canceled more than 2,400 research projects, the respected journal Nature reported on June 27. Trump's budget cuts to U.S. science are 'unprecedented,' and could have 'catastrophic effects,' Nature said in an earlier report on May. 15. The Trump administration says the NIH, NSF, NASA and other government-funded scientific institutions were rife with waste and politically-motivated 'woke' programs, and needed to be made more efficient. Many grants were awarded under non-scientific diversity, equity and inclusion (DEI) requirements that the Trump administration has now terminated, administration officials say. But most scientists say that, while there's probably some degree of waste in any large organization, Trump's budget cuts are a catastrophic overreaction. The administration is killing research programs that could save millions of lives in America and around the world, as well as crippling U.S. innovation in cutting-edge industries. Rep. Bill Foster, D-Illinois, the only member of Congress with a PhD in physics, told me in an interview that 'Trump is wrecking American science.' He added, 'I understand why you would have to cut things, including science. But this is done in a very sloppy and, frankly, stupid way.' Trump's budget cutters have simply looked for science programs that had the terms 'diversity,' or 'inclusion' somewhere in their paperwork, regardless of their merit, critics say. In many cases, such words were just included pro forma in top-quality scientific research programs. Foster told me he already knows of cases in which professors working on five-year research programs have just learned that their last year of funding is being cut off. They have had to lay off their research teams, leading many scientists to seek jobs abroad. 'Right now, America is bleeding scientific talent,' Foster told me. While much of the U.S. scientific leadership was built thanks to European scientists who moved to America in World War II, such as Nobel laureate Albert Einstein, the reverse trend is taking place now, he added. Indeed, French President Emmanuel Macron and European Commission President Ursula von der Leyen recently announced a $566 million plan at Sorbonne University to lure U.S. science refugees. The program is officially called 'Choose Europe for Science.' In an obvious reference to the United States, Macron said at the announcement ceremony that 'Nobody could imagine a few years ago that one of the great democracies of the world would eliminate research programs on the pretext that the word 'diversity' appeared in its program,' according to a New York Times report. When I asked Foster why he thinks Trump is crippling America's scientific programs, he said, 'I think he's trying to achieve popularity with his base, which comes largely from rural areas.' He added that people living in rural areas may not be fully aware of the benefits of science, and are more likely to blame intellectuals and scientists for the country's problems. Maybe so. But whatever the reason, crippling U.S. science will have dire consequences. America will pay not just in lost discoveries, but in lost lives, lost leadership and a diminished future for generations to come. Don't miss the 'Oppenheimer Presenta' TV show on Sundays at 9 pm E.T. on CNN en Español. Blog:
Yahoo
2 days ago
- Yahoo
Cognito achieves enrolment target in trial of Spectris system for Alzheimer's
Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris AD system's efficacy and safety in treating Alzheimer's disease. The double-blind trial, with 670 subjects enrolled, is set to use the company's neuromodulating device at home for 12 months. Carried out across 70 US clinical sites, the trial will be followed by a 12-month open-label extension trial. According to the company, the Spectris AD system will deliver synchronised light and sound stimulation at the 40Hz gamma frequency, which has previously shown promise in the OVERTURE feasibility study by preserving corpus callosum structure in subjects with Alzheimer's. Results from the study indicated a 76% and 77% decrease in cognitive and functional decline, respectively, and significant white matter preservation with a 69% decrease in whole brain atrophy over six months. Subjects in the HOPE Study's treatment group will receive Active Sensory Stimulation System treatment once a day while the control group will use a Sham Sensory Stimulation System. Study visits for consent, screening, and baseline assessments are scheduled, followed by three, six, nine (by phone), 12, and 13 months safety follow-ups. The primary aim of the study is to evaluate Spectris' efficacy in slowing Alzheimer's progression against sham for mild to moderate patients, measured functionally by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) assessment and the Mini-Mental State Exam (MMSE). A subset of clinical sites will participate in a substudy to assess additional fluid biomarkers. Subjects at these sites will undergo lumbar punctures to collect cerebrospinal fluid at baseline, three months, and 12 months. Cognito Therapeutics CEO Christian Howell said: 'Completing enrolment in this landmark trial marks a major step forward in our mission to deliver a better treatment option for people living with neurodegenerative conditions such as Alzheimer's.' The system remains investigational and is not yet available for sale. In 2023, Cognito secured $73m in Series B funding to further develop its wearable neuromodulation device for Alzheimer's. "Cognito achieves enrolment target in trial of Spectris system for Alzheimer's" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
3 days ago
- Miami Herald
Mayo Clinic's AI tool identifies 9 dementia types, including Alzheimer's, with one scan
ROCHESTER, Minn. - Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan - a transformative advance in early, accurate diagnosis. The tool, StateViewer, helped researchers identify the dementia type in 88% of cases, according to research published online on June 27, 2025, in Neurology, the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. Researchers trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment. This innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise. The rising toll of dementia Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists. StateViewer was developed under the direction of David Jones, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neurology Artificial Intelligence Program. 'Every patient who walks into my clinic carries a unique story shaped by the brain's complexity,' Dr. Jones says. 'That complexity drew me to neurology and continues to drive my commitment to clearer answers. StateViewer reflects that commitment - a step toward earlier understanding, more precise treatment and, one day, changing the course of these diseases.' To bring that vision to life, Dr. Jones worked alongside Leland Barnard, Ph.D., a data scientist who leads the AI engineering behind StateViewer. 'As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions,' Dr. Barnard says. 'Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine.' Turning brain patterns into clinical insight The tool analyzes a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia. Alzheimer's typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behavior. StateViewer displays these patterns through color-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis. Mayo Clinic researchers plan to expand the tool's use and will continue evaluating its performance in a variety of clinical settings. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.